Filament loaded with active molecules for 3D printing
Advanced filaments embedded with active pharmaceutical ingredients for FDM 3D printing, enabling personalized medicine and dietary supplements. Developed by ULiège's Laboratory of Pharmaceutical Technology, these filaments allow precise dosing for patient-specific needs.
Overview
The Laboratory of Pharmaceutical Technology at ULiège has developed an innovative solution for integrating active pharmaceutical ingredients into filaments suitable for FDM 3D printing. This technology enables the production of personalized medicine by allowing the precise dosing and on-demand printing of pharmaceuticals tailored to individual patient needs. The filaments have been successfully embedded with molecules such as theophylline, caffeine, and melatonin, showcasing their versatility and potential in the pharmaceutical and dietary supplement sectors.
Technical specifications
- Filament Composition: Designed for use with FDM 3D printers, these filaments are loaded with active molecules.
- Active Ingredients: Compatible with a range of molecules, including pharmaceuticals like theophylline, caffeine, and melatonin.
- Production Expertise: Utilizes over 20 years of experience in hot-melt extrusion technology, ensuring high-quality filament production.
- Applications: Initially developed for pharmaceuticals, with ongoing adaptation for dietary supplements to facilitate taste and palatability testing.
- Equipment: Equipped for pharmaceutical-grade production and more flexible standards for dietary supplements.
Technology readiness level
This technology is currently at TRL 4, indicating that it has been validated in a laboratory environment but requires further development and testing to reach higher readiness levels. Future plans include adapting the technology for dietary supplements and conducting human palatability tests.
About Université de Liège
Université de Liège is a comprehensive public research university with a broad academic portfolio and campuses centered at Sart‑Tilman and in the city, serving its region and international partners. For industry, co‑located laboratories sit alongside the CHU de Liège university hospital, enabling clinical and translational collaboration. The adjacent Liège Science Park hosts companies next to university research, fostering joint R&D and day‑to‑day interaction. Research is backed by competitive European and Belgian funding, including Horizon Europe, the national science foundation (F.R.S.–FNRS), and programs of the Walloon Region. Industry engagement is streamlined through Interface Entreprises; with Gesval, it handles IP protection, licensing, and investment to speed commercialization.
delivered to your inbox.